International Journal of Medical Sciences has published an Austrian study with UBC® Rapid performed at the Department of Urology, Medical University of Innsbruck. Urinary samples were analyzed by cytology, UBC® Rapid and NMP22 BladderChek® test. 

The results from this study coincide very well with the results from previous reported studies, with a very high UBC® Rapid sensitivity for in particular high grade bladder cancer tumors compared to both cytology and NMP22 BladderChek® test.

Bladder cancer is a common and resource-intensive cancer. Patients often need extensive and long-term follow-up after primary diagnosis. Methods for early detection and regular follow-up are of great importance.

Cystoscopy, a procedure in which the inside of the bladder is examined using an optical instrument, is the most commonly used method for detection of bladder cancer.

The use of urine-based markers in evaluation of bladder cancer is an interesting approach since the tumors are constantly in contact with urine. UBC® Rapid is a non-invasive test detecting cytokeratin 8 and 18 fragments released from urothelial cells into the urine as markers for bladder cancer. UBC® Rapid combined with a reader is the first quantitative point-of-care system for bladder cancer, enabling risk stratification in a point-of-care setting.

For further information please contact:

IDL Biotech AB (publ)

Charlotte Berg, CEO

+46 8 799 67 50